Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gazzard

Showing results (211-220 of 221) with videos related to

Pageof 23
Sort By:
HIV Medicine|September 8, 2009
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson, S-L Man, A Copas, et al.
HIV Medicine|May 17, 2011
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) studyR A Hughes, J A C Sterne, J Walsh, et al.
Neurology|February 23, 2011
Antiretroviral therapy CNS penetration and HIV-1-associated CNS diseaseL Garvey, A Winston, J Walsh, et al.
HIV Medicine|February 24, 2006
Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wastingJ Gold, M J Batterham, H Rekers, et al.
Nature Medicine|December 29, 1999
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapyM E Sharkey, I Teo, T Greenough, et al.
The New England Journal of Medicine|December 1, 2006
CD4+ count-guided interruption of antiretroviral treatment, W M El-Sadr, J D Lundgren, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
HIV Medicine|October 25, 2019
The EuroSIDA study: 25 years of scientific achievementsK Laut, O Kirk, J Rockstroh, et al.
Plos One|November 13, 2015
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 StudyD Raben, A Mocroft, M Rayment, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
Pageof 23

Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
HIV Medicine|September 8, 2009
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson, S-L Man, A Copas, et al.
HIV Medicine|May 17, 2011
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) studyR A Hughes, J A C Sterne, J Walsh, et al.
Neurology|February 23, 2011
Antiretroviral therapy CNS penetration and HIV-1-associated CNS diseaseL Garvey, A Winston, J Walsh, et al.
HIV Medicine|February 24, 2006
Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wastingJ Gold, M J Batterham, H Rekers, et al.
Nature Medicine|December 29, 1999
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapyM E Sharkey, I Teo, T Greenough, et al.
The New England Journal of Medicine|December 1, 2006
CD4+ count-guided interruption of antiretroviral treatment, W M El-Sadr, J D Lundgren, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
HIV Medicine|October 25, 2019
The EuroSIDA study: 25 years of scientific achievementsK Laut, O Kirk, J Rockstroh, et al.
Plos One|November 13, 2015
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 StudyD Raben, A Mocroft, M Rayment, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
Pageof 23